Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure in patients with poorly controlled intraocular pressure on maximally tolerated medical therapy or prior failed laser trabeculoplasty.
This is a multi-center, outpatient study assessing equivalence of the Titanium Sapphire laser (TiSaLT) to the Argon laser (ALT) in the ability to reduce IOP in patients having primary open angle glaucoma in eyes with poorly controlled IOP on maximally tolerated medications and/or prior failed glaucoma surgery. Approximately 120 patients are to be enrolled in the study, with approximately equal numbers of patients enrolled at each of the investigational sites. The investigational sites are to accrue patients with poorly controlled open-angle glaucoma on maximal tolerated medical therapy and/or patients with previously failed laser trabeculoplasty. One half of the eyes will be randomized to treatment with the Argon laser (ALT) as the concurrent control group and the other half will be treated with Titanium Sapphire (TiSaLT) laser.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Spot laser treatment, \~50 spots over 180°
Spot laser treatment, \~50 spots over 180°
North Bay Eye Associates
Petaluma, California, United States
International Eye Care
Tampa, Florida, United States
Glaucoma Associates of New York
New York, New York, United States
Texan Eye Care
Intraocular Pressure (IOP)
Time frame: 1 year
Adverse event frequency
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Austin, Texas, United States
Mann Eye Institute
Houston, Texas, United States
Credit Valley EyeCare
Mississauga, Ontario, Canada
Institut du Glaucome de Montréal
Montreal, Quebec, Canada
Sourasky Medical Center
Tel Aviv, Israel
Sheba Medical Center
Tel Litwinsky, Israel
Hospital Clinico San Carlos de Madrid
Madrid, Spain